Comment on

• Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease.

  Desreumaux P, Foussat A, Allez M, Beaugerie L, Hébuterne X, Bouhnik Y, Nachury M, Brun V, Bastian H, Belmonte N, Ticchioni M, Duchange A, Morel-Mandrino P, Neveu V, Clerget-Chossat N, Forte M, Colombel JF. Desreumaux P, et al. Gastroenterology. 2012 Nov;143(5):1207-1217.e2. doi: 10.1053/j.gastro.2012.07.116. Epub 2012 Aug 8. Gastroenterology. 2012. PMID: 22885333 Clinical Trial.
• Intestinal stem cell growth and differentiation on a tubular scaffold with evaluation in small and large animals.

  Shaffiey SA, Jia H, Keane T, Costello C, Wasserman D, Quidgley M, Dziki J, Badylak S, Sodhi CP, March JC, Hackam DJ. Shaffiey SA, et al. Regen Med. 2016 Jan;11(1):45-61. doi: 10.2217/rme.15.70. Epub 2015 Sep 23. Regen Med. 2016. PMID: 26395928 Free PMC article.
• Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial.

  Hawkey CJ, Allez M, Clark MM, Labopin M, Lindsay JO, Ricart E, Rogler G, Rovira M, Satsangi J, Danese S, Russell N, Gribben J, Johnson P, Larghero J, Thieblemont C, Ardizzone S, Dierickx D, Ibatici A, Littlewood T, Onida F, Schanz U, Vermeire S, Colombel JF, Jouet JP, Clark E, Saccardi R, Tyndall A, Travis S, Farge D. Hawkey CJ, et al. JAMA. 2015 Dec 15;314(23):2524-34. doi: 10.1001/jama.2015.16700. JAMA. 2015. PMID: 26670970 Clinical Trial.
• Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial.

  Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Panés J, et al. Lancet. 2016 Sep 24;388(10051):1281-90. doi: 10.1016/S0140-6736(16)31203-X. Epub 2016 Jul 29. Lancet. 2016. PMID: 27477896 Clinical Trial.